Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Kieran Adam"'
Autor:
Brian S Henick, Xizi Hu, Shoiab M Bukhari, Carly Tymm, Kieran Adam, Shalom Lerrer, Robert J Winchester, Adam Mor
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall
Externí odkaz:
https://doaj.org/article/ff1fa2cc84b64b689bab96d49de5afa5
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 27, Iss , Pp 380-390 (2022)
The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes.
Externí odkaz:
https://doaj.org/article/7b309f1b92964a77bed8276d7e43199e
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-10 (2021)
Strazza et al. show that phosphoprotein associated with glycosphingolipidenriched microdomains 1 (PAG) is phosphorylated following PD-1 ligation. They find that PAG deletion sensitizes tumors to PD-1 blockade. This study suggests PAG as a critical me
Externí odkaz:
https://doaj.org/article/6881d1a3b36f43a4a4454129bbd534d2
Autor:
Kieran Adam, Adam Mor
Publikováno v:
Bio-Protocol, Vol 12, Iss 14 (2022)
Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin con
Externí odkaz:
https://doaj.org/article/0eea449068e645dd85f41af67eb2c87a
Publikováno v:
iScience, Vol 24, Iss 9, Pp 103020- (2021)
Summary: Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a
Externí odkaz:
https://doaj.org/article/ad4611e681ec4299af2a0f3e9580172c
Publikováno v:
Data in Brief, Vol 37, Iss , Pp 107168- (2021)
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity, but many patients do not respond, and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understan
Externí odkaz:
https://doaj.org/article/d423118f5e1340a1a91159b7cb62d516
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246168 (2021)
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkp
Externí odkaz:
https://doaj.org/article/a7c52814cb354010bb8f091162d087e6
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218109 (2019)
The signaling lymphocytic activation molecule (SLAM) family is comprised of nine distinct receptors that are expressed exclusively on hematopoietic cells. Most of these transmembrane receptors are homotypic by nature and downstream signaling occurs w
Externí odkaz:
https://doaj.org/article/07863df3c0df4d878eb46a34ffa8ad01
Publikováno v:
Immunol Lett
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity but many patients do not respond and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand
Autor:
Sabina Sandigursky, Adam Mor, Johanna Straube, Marianne Strazza, Kieran Adam, Shalom Lerrer, Beatrix Ueberheide
Publikováno v:
Inflammation
PD-1 is a critical therapeutic target in cancer immunotherapy and antibodies blocking PD-1 are approved for multiple types of malignancies. The phosphatase SHP2 is the main effector mediating PD-1 downstream signaling and accordingly attempts have be